Skip to main content
. 2024 Oct 14;60(10):1684. doi: 10.3390/medicina60101684

Table A4.

Hypothesis test summary for MIDAS score distribution across Erenumab and Topiramate treatment groups.

Null Hypothesis Test Sig. Decision
1 The distribution of MIDAS After is the same across categories of Erenumab/Topiramate. Independent Samples Mann–Whitney U Test 0.560 Retain the null hypothesis *

* Asymptotic significances are displayed. The significance level is 0.050.